Literature DB >> 16809296

Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity.

Jennifer E Foulkes1, Moses Prabu-Jeyabalan, Deyna Cooper, Gavin J Henderson, Janera Harris, Ronald Swanstrom, Celia A Schiffer.   

Abstract

Sequence variability associated with human immunodeficiency virus type 1 (HIV-1) is useful for inferring structural and/or functional constraints at specific residues within the viral protease. Positions that are invariant even in the presence of drug selection define critically important residues for protease function. While the importance of conserved active-site residues is easily understood, the role of other invariant residues is not. This work focuses on invariant Thr80 at the apex of the P1 loop of HIV-1, HIV-2, and simian immunodeficiency virus protease. In a previous study, we postulated, on the basis of a molecular dynamics simulation of the unliganded protease, that Thr80 may play a role in the mobility of the flaps of protease. In the present study, both experimental and computational methods were used to study the role of Thr80 in HIV protease. Three protease variants (T80V, T80N, and T80S) were examined for changes in structure, dynamics, enzymatic activity, affinity for protease inhibitors, and viral infectivity. While all three variants were structurally similar to the wild type, only T80S was functionally similar. Both T80V and T80N had decreased the affinity for saquinavir. T80V significantly decreased the ability of the enzyme to cleave a peptide substrate but maintained infectivity, while T80N abolished both activity and viral infectivity. Additionally, T80N decreased the conformational flexibility of the flap region, as observed by simulations of molecular dynamics. Taken together, these data indicate that HIV-1 protease functions best when residue 80 is a small polar residue and that mutations to other amino acids significantly impair enzyme function, possibly by affecting the flexibility of the flap domain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809296      PMCID: PMC1489026          DOI: 10.1128/JVI.01900-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.

Authors:  Hiroyasu Ohtaka; Adrian Velázquez-Campoy; Dong Xie; Ernesto Freire
Journal:  Protein Sci       Date:  2002-08       Impact factor: 6.725

Review 2.  Win some, lose some: enthalpy-entropy compensation in weak intermolecular interactions.

Authors:  J D Dunitz
Journal:  Chem Biol       Date:  1995-11

3.  The regulation of sequential processing of HIV-1 Gag by the viral protease.

Authors:  S C Pettit; N Sheng; R Tritch; S Erickson-Viitanen; R Swanstrom
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

4.  Fidelity of two retroviral reverse transcriptases during DNA-dependent DNA synthesis in vitro.

Authors:  J D Roberts; B D Preston; L A Johnston; A Soni; L A Loeb; T A Kunkel
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

5.  The accuracy of reverse transcriptase from HIV-1.

Authors:  J D Roberts; K Bebenek; T A Kunkel
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

6.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.

Authors:  S V Gulnik; L I Suvorov; B Liu; B Yu; B Anderson; H Mitsuya; J W Erickson
Journal:  Biochemistry       Date:  1995-07-25       Impact factor: 3.162

7.  Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins.

Authors:  J Tözsér; I Bláha; T D Copeland; E M Wondrak; S Oroszlan
Journal:  FEBS Lett       Date:  1991-04-09       Impact factor: 4.124

8.  Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance.

Authors:  W R Scott; C A Schiffer
Journal:  Structure       Date:  2000-12-15       Impact factor: 5.006

9.  Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.

Authors:  Nancy M King; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Piet Wigerinck; Marie-Pierre de Béthune; Celia A Schiffer
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

10.  Fidelity of HIV-1 reverse transcriptase copying RNA in vitro.

Authors:  J P Ji; L A Loeb
Journal:  Biochemistry       Date:  1992-02-04       Impact factor: 3.162

View more
  21 in total

1.  Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study.

Authors:  Salerwe Mosebi; Lynn Morris; Heini W Dirr; Yasien Sayed
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

2.  Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.

Authors:  Fengling Liu; Andrey Y Kovalevsky; Yunfeng Tie; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2008-07-01       Impact factor: 5.469

3.  Structure of the unbound form of HIV-1 subtype A protease: comparison with unbound forms of proteases from other HIV subtypes.

Authors:  Arthur H Robbins; Roxana M Coman; Edith Bracho-Sanchez; Marty A Fernandez; C Taylor Gilliland; Mi Li; Mavis Agbandje-McKenna; Alexander Wlodawer; Ben M Dunn; Robert McKenna
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-02-12

4.  Predicting X-ray solution scattering from flexible macromolecules.

Authors:  Hao Zhou; Hugo Guterres; Carla Mattos; Lee Makowski
Journal:  Protein Sci       Date:  2018-10-16       Impact factor: 6.725

5.  Carbamylation of N-terminal proline.

Authors:  Folasade M Olajuyigbe; Nicola Demitri; Joshua O Ajele; Elisa Maurizio; Lucio Randaccio; Silvano Geremia
Journal:  ACS Med Chem Lett       Date:  2010-06-02       Impact factor: 4.345

6.  Modulation of HIV protease flexibility by the T80N mutation.

Authors:  Hao Zhou; Shangyang Li; John Badger; Ellen Nalivaika; Yufeng Cai; Jennifer Foulkes-Murzycki; Celia Schiffer; Lee Makowski
Journal:  Proteins       Date:  2015-09-29

7.  Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.

Authors:  Jennifer E Foulkes-Murzycki; Christina Rosi; Nese Kurt Yilmaz; Robert W Shafer; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2012-12-27       Impact factor: 5.100

8.  A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket.

Authors:  Kelly L Damm; Peter M U Ung; Jerome J Quintero; Jason E Gestwicki; Heather A Carlson
Journal:  Biopolymers       Date:  2008-08       Impact factor: 2.505

9.  Co-lethality studied as an asset against viral drug escape: the HIV protease case.

Authors:  Sophie Brouillet; Thomas Valere; Emmanuelle Ollivier; Laurent Marsan; Anne Vanet
Journal:  Biol Direct       Date:  2010-06-17       Impact factor: 4.540

10.  In pursuit of virtual lead optimization: pruning ensembles of receptor structures for increased efficiency and accuracy during docking.

Authors:  Erin S D Bolstad; Amy C Anderson
Journal:  Proteins       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.